​

Neuphoria Therapeutics Stock (NASDAQ:NEUP)

ForecastRevenueOwnershipFinancialsChart
Neuphoria Therapeutics by TradingView

Previous Close

$4.67

52W Range

$2.12 - $16.08

50D Avg

$3.54

200D Avg

$6.99

Market Cap

$8.00M

Avg Vol (3M)

$1.32M

Beta

0.26

Div Yield

-

NEUP Company Profile

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

24

IPO Date

Dec 16, 2021

Website

NEUP Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceJun 22
Licences$263.63K

Fiscal year ends in Jun 24 | Currency in USD

NEUP Financial Summary

Jun 24Jun 23Jun 22
Revenue-$20.00K$260.00K
Operating Income$-17.89B$-31.97M$-21.34M
Net Income$-15.49B$-31.85M$-21.76M
EBITDA$-17.89B$-17.87M$-11.51M
Basic EPS$-0.01$-0.02$-0.02
Diluted EPS$-0.01$-0.02$-0.02

Fiscal year ends in Jun 24 | Currency in USD